Cosmo N.V. (SWX:COPN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 1.17B +38.0% |
| Revenue (ttm) | 96.99M -61.0% |
| Net Income | -3.36M |
| EPS | -0.21 |
| Shares Out | 16.19M |
| PE Ratio | n/a |
| Forward PE | 1,115.24 |
| Dividend | 1.92 (2.65%) |
| Ex-Dividend Date | Apr 24, 2026 |
| Volume | 14,206 |
| Open | 72.00 |
| Previous Close | 72.50 |
| Day's Range | 70.50 - 72.00 |
| 52-Week Range | 53.40 - 129.40 |
| Beta | 1.48 |
| Analysts | Strong Buy |
| Price Target | 129.22 (+80.73%) |
| Earnings Date | Jul 23, 2026 |
About Cosmo
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral ... [Read more]
Analyst Summary
According to 5 analysts, the average rating for COPN stock is "Strong Buy." The 12-month stock price target is CHF 129.22, which is an increase of 80.73% from the latest price.
News
Cosmo price target raised to CHF 160 from CHF 130 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Cosmo Pharmaceuticals (CMOPF) to CHF 160 from CHF 130 and keeps a Buy rating on the shares. The firm cites the addition…
Cosmo Earnings Call Transcript: H2 2025
Structural transformation delivered, with 2025 revenue of EUR 104.2 million (85% recurring), EBITDA of EUR 9.5 million, and strong growth in GI Genius and Winlevi. 2026 guidance targets double-digit recurring revenue growth, expanding EBITDA, and a robust cash position.
Cosmo Earnings release: H2 2025
Cosmo released its H2 2025 earnings on March 9, 2026, summarizing the period's financial results.
Cosmo Annual report: H2 2025
Cosmo has published its H2 2025 annual report on March 9, 2026.
Cosmo Slides: H2 2025
Cosmo has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 9, 2026.
Cosmo Earnings Call Transcript: H1 2025
H1 2025 saw strong revenue and EBITDA growth, driven by GI Genius and Winlevi, with raised full-year guidance. Strategic focus remains on clinical pipeline advancement, AI medtech expansion, and regulatory milestones, supported by a robust cash position.
Cosmo Quarterly report: H1 2025
Cosmo has published its H1 2025 quarterly earnings report on July 23, 2025.
Cosmo Slides: H1 2025
Cosmo has posted slides in relation to its H1 2025 quarterly earnings report, which was published on July 23, 2025.
Cosmo Transcript: Investor Day 2025
A new 2030 vision targets 39% annual revenue growth, driven by AI-enabled MedTech, global expansion of Winlevi, and the launch of Breezula for hair loss. Strategic focus on gut, skin, and AI, plus digital health, positions the business for high-margin, sustainable growth.
Cosmo Slides: FY 2025
Cosmo has posted slides in relation to its FY 2025 quarterly earnings report, which was published on July 1, 2025.